FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588546708> ?p ?o ?g. }

• W2588546708 endingPage "vi32" @default.
• W2588546708 startingPage "vi32" @default.
• W2588546708 abstract "In the current study, we performed a complete analysis of gene amplification, copy-number variations (CNV), transcriptional profiling and protein expression of all four HER family receptors, in a series of patients with metastatic breast cancer (MBC), treated with trastuzumab-based regimens. In addition, our analysis included the evaluation of several other factors, such as PTEN and mTOR protein expression by immunohistochemistry (IHC) and PIK3CA mutations. Formalin-fixed paraffin-embedded tumor tissue samples were collected from 229 patients, considered to be HER2-positive when assessed at the local laboratories. Central review of HER2 status by fluorescence in situ hybridization and/or IHC revealed that of the 229 patients, only 139 (61%) were truly HER2-positive. In the multivariate analysis, HER3 gene amplification (using the 75th percentile as a cut-off point) (HR = 0.50, 95% CI 0.27-0.93, p = 0.027), HER3 mRNA expression (75th percentile as a cut-off point) (HR = 0.47, 95% CI 0.22-1.01, p = 0.052) and PTEN protein expression (HR = 0.60, 95% CI 0.37-0.98, p = 0.042) retained their favorable prognostic significance for OS in the HER2-positive subgroup. In HER2-negative patients, none of the significant factors that were identified in the univariate analysis retained prognostic ability for OS. Moreover, wild-type PIK3CA was found to be an independent favorable prognostic factor for TTP in the HER2-positive patients (HR = 0.53, 95% CI 0.27-1.02, p = 0.059). In addition, EGFR CNVs (HR = 4.89, 95% CI 1.23-19.36, p = 0.024), HER3 gene amplification (using the median value as a cut-off point) (HR = 0.41, 95% CI 0.16-1.06, p = 0.067), HER3 protein expression (HR = 0.15, 95% CI 0.04-0.52, p = 0.003) and mTOR protein expression (HR = 0.33, 95% CI 0.13-0.84, p = 0.02) independently affected TTP in the HER2-negative subgroup. The present study suggests that EGFR is a negative, whereas HER3 is a positive prognostic factor in patients with MBC. Since the above associations were not restricted to HER2-positive patients only, a definitive predictive value for trastuzumab treatment is not documented. Given the retrospective nature of the current analysis, our findings should be considered as hypothesis generating." @default.
• W2588546708 created "2017-02-24" @default.
• W2588546708 creator A5002833730 @default.
• W2588546708 creator A5005079253 @default.
• W2588546708 creator A5005181965 @default.
• W2588546708 creator A5005730021 @default.
• W2588546708 creator A5006017501 @default.
• W2588546708 creator A5007991935 @default.
• W2588546708 creator A5011320926 @default.
• W2588546708 creator A5015437737 @default.
• W2588546708 creator A5026269698 @default.
• W2588546708 creator A5042908077 @default.
• W2588546708 creator A5044696839 @default.
• W2588546708 creator A5046910601 @default.
• W2588546708 creator A5048212045 @default.
• W2588546708 creator A5051365519 @default.
• W2588546708 creator A5054018815 @default.
• W2588546708 creator A5054217868 @default.
• W2588546708 creator A5055539716 @default.
• W2588546708 creator A5057164541 @default.
• W2588546708 creator A5069742421 @default.
• W2588546708 creator A5084537623 @default.
• W2588546708 date "2016-10-01" @default.
• W2588546708 modified "2023-09-30" @default.
• W2588546708 title "Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer" @default.
• W2588546708 doi "https://doi.org/10.1093/annonc/mdw363.52" @default.
• W2588546708 hasPublicationYear "2016" @default.
• W2588546708 type Work @default.
• W2588546708 sameAs 2588546708 @default.
• W2588546708 citedByCount "1" @default.
• W2588546708 countsByYear W25885467082018 @default.
• W2588546708 crossrefType "journal-article" @default.
• W2588546708 hasAuthorship W2588546708A5002833730 @default.
• W2588546708 hasAuthorship W2588546708A5005079253 @default.
• W2588546708 hasAuthorship W2588546708A5005181965 @default.
• W2588546708 hasAuthorship W2588546708A5005730021 @default.
• W2588546708 hasAuthorship W2588546708A5006017501 @default.
• W2588546708 hasAuthorship W2588546708A5007991935 @default.
• W2588546708 hasAuthorship W2588546708A5011320926 @default.
• W2588546708 hasAuthorship W2588546708A5015437737 @default.
• W2588546708 hasAuthorship W2588546708A5026269698 @default.
• W2588546708 hasAuthorship W2588546708A5042908077 @default.
• W2588546708 hasAuthorship W2588546708A5044696839 @default.
• W2588546708 hasAuthorship W2588546708A5046910601 @default.
• W2588546708 hasAuthorship W2588546708A5048212045 @default.
• W2588546708 hasAuthorship W2588546708A5051365519 @default.
• W2588546708 hasAuthorship W2588546708A5054018815 @default.
• W2588546708 hasAuthorship W2588546708A5054217868 @default.
• W2588546708 hasAuthorship W2588546708A5055539716 @default.
• W2588546708 hasAuthorship W2588546708A5057164541 @default.
• W2588546708 hasAuthorship W2588546708A5069742421 @default.
• W2588546708 hasAuthorship W2588546708A5084537623 @default.
• W2588546708 hasBestOaLocation W25885467081 @default.
• W2588546708 hasConcept C104317684 @default.
• W2588546708 hasConcept C121608353 @default.
• W2588546708 hasConcept C126322002 @default.
• W2588546708 hasConcept C143998085 @default.
• W2588546708 hasConcept C144301174 @default.
• W2588546708 hasConcept C190283241 @default.
• W2588546708 hasConcept C204232928 @default.
• W2588546708 hasConcept C2775930923 @default.
• W2588546708 hasConcept C2777542201 @default.
• W2588546708 hasConcept C2777609662 @default.
• W2588546708 hasConcept C2779786085 @default.
• W2588546708 hasConcept C30481170 @default.
• W2588546708 hasConcept C38180746 @default.
• W2588546708 hasConcept C530470458 @default.
• W2588546708 hasConcept C55493867 @default.
• W2588546708 hasConcept C71924100 @default.
• W2588546708 hasConcept C86554907 @default.
• W2588546708 hasConcept C86803240 @default.
• W2588546708 hasConceptScore W2588546708C104317684 @default.
• W2588546708 hasConceptScore W2588546708C121608353 @default.
• W2588546708 hasConceptScore W2588546708C126322002 @default.
• W2588546708 hasConceptScore W2588546708C143998085 @default.
• W2588546708 hasConceptScore W2588546708C144301174 @default.
• W2588546708 hasConceptScore W2588546708C190283241 @default.
• W2588546708 hasConceptScore W2588546708C204232928 @default.
• W2588546708 hasConceptScore W2588546708C2775930923 @default.
• W2588546708 hasConceptScore W2588546708C2777542201 @default.
• W2588546708 hasConceptScore W2588546708C2777609662 @default.
• W2588546708 hasConceptScore W2588546708C2779786085 @default.
• W2588546708 hasConceptScore W2588546708C30481170 @default.
• W2588546708 hasConceptScore W2588546708C38180746 @default.
• W2588546708 hasConceptScore W2588546708C530470458 @default.
• W2588546708 hasConceptScore W2588546708C55493867 @default.
• W2588546708 hasConceptScore W2588546708C71924100 @default.
• W2588546708 hasConceptScore W2588546708C86554907 @default.
• W2588546708 hasConceptScore W2588546708C86803240 @default.
• W2588546708 hasLocation W25885467081 @default.
• W2588546708 hasOpenAccess W2588546708 @default.
• W2588546708 hasPrimaryLocation W25885467081 @default.
• W2588546708 hasRelatedWork W1973483870 @default.
• W2588546708 hasRelatedWork W1999070116 @default.
• W2588546708 hasRelatedWork W2218832708 @default.
• W2588546708 hasRelatedWork W2316882881 @default.
• W2588546708 hasRelatedWork W2401868633 @default.
• W2588546708 hasRelatedWork W2422466133 @default.

• next